Rahnama Maryam, Ghasemzadeh Navid, Latifi Zeinab, Kheradmand Fatemeh, Koukia Fariba Abbasi, Sharun Khan, Golchin Ali
Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran; Department of Applied Cell Sciences, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran; Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Eur J Pharmacol. 2025 Aug 5;1000:177726. doi: 10.1016/j.ejphar.2025.177726. Epub 2025 May 9.
The acquisition of suitable stem cell sources is a significant issue in regenerative medicine. There has been considerable interest in utilizing mesenchymal stem cells (MSCs) derived from endometrial and menstrual blood as a promising resource of MSCs, owing to their unique biochemical properties and prospective use in clinical therapies. This population of stem cells has distinct characteristics in terms of immunophenotype, proliferation rate, and differentiation capacity. A notable characteristic of these stem cells is their capacity to develop into mesodermal lineages, highlighting their regenerative capability. Moreover, the presence of certain surface markers facilitates the augmentation of clonogenic endometrial MSCs. Their distinctive characteristics, along with their swift multiplication ability, underscore their significant promise for therapeutic applicability in regenerative medicine and cell-based treatments. Current investigations are examining possible usage of diverse stem cell resources in the treatment of inflammatory diseases and perhaps intractable illnesses like Parkinson's disease, utilizing their immunomodulatory properties. This review aims to analyze stem cell-related research that has utilized endometrial and menstrual blood-derived MSCs (enMSCs and MenSCs) with a special focus on their clinical application. We will explore the existing evidence about the therapeutic potential for these stem cells across many medical diseases and address the obstacles and prospective trajectories in this domain. Additionally, we will study the unique properties of enMSCs and MenSCs that make them promising candidates for regenerative medicine.
获取合适的干细胞来源是再生医学中的一个重要问题。由于其独特的生化特性以及在临床治疗中的潜在用途，利用源自子宫内膜和月经血的间充质干细胞（MSCs）作为一种有前景的MSCs来源受到了广泛关注。这群干细胞在免疫表型、增殖率和分化能力方面具有独特的特征。这些干细胞的一个显著特点是它们能够分化为中胚层谱系，突出了它们的再生能力。此外，某些表面标志物的存在有助于增强克隆性子宫内膜间充质干细胞。它们独特的特征以及快速增殖的能力，强调了它们在再生医学和基于细胞的治疗中的治疗应用潜力。目前的研究正在探讨利用不同干细胞来源治疗炎症性疾病以及诸如帕金森病等难治性疾病的可能性，利用它们的免疫调节特性。本综述旨在分析利用子宫内膜和月经血来源的间充质干细胞（enMSCs和MenSCs）的干细胞相关研究，特别关注它们的临床应用。我们将探讨关于这些干细胞在多种医学疾病中的治疗潜力的现有证据，并解决该领域的障碍和未来发展轨迹。此外，我们将研究使enMSCs和MenSCs成为再生医学有前景候选者 的独特特性。
